Platelet glycoprotein IIb/IIIa inhibitors reduce mortality in diabetic patients with non-ST-segment-elevation acute coronary syndromes. - Wikidata - awgldk - TriplyDB

Platelet glycoprotein IIb/IIIa inhibitors reduce mortality in diabetic patients with non-ST-segment-elevation acute coronary syndromes.

Platelet glycoprotein IIb/IIIa inhibitors reduce mortality in diabetic patients with non-ST-segment-elevation acute coronary syndromes.

http://www.wikidata.org/entity/Q43815690

about

Risk factors in coronary atherosclerosis athero-inflammation: the meeting point Personalized antiplatelet therapy with P2Y12 receptor inhibitors: benefits and pitfalls Antiplatelet agents in atherothrombotic diseases Stent thrombosis associated with first-generation drug-eluting stents: issues with antiplatelet therapy Platelet inhibitors in non-ST-segment elevation acute coronary syndromes and percutaneous coronary intervention: glycoprotein IIb/IIIa inhibitors, clopidogrel, or both?Acute coronary syndromes: diagnosis and management, part I The Role of Glycoprotein IIb/IIIa Inhibitors- A Promise Not Kept?Abciximab as an adjunctive therapy for patients undergoing percutaneous coronary interventions.Use of platelet glycoprotein IIb/IIIa inhibitors in diabetics undergoing PCI for non-ST-segment elevation acute coronary syndromes: impact of clinical status and procedural characteristics.Oral antiplatelet therapy in diabetes mellitus and the role of prasugrel: an overview.Vorapaxar in patients with diabetes mellitus and previous myocardial infarction: findings from the thrombin receptor antagonist in secondary prevention of atherothrombotic ischemic events-TIMI 50 trial.Pharmacogenomics of cardiovascular complications in diabetes and obesity.Increased atherothrombotic burden in patients with diabetes mellitus and acute coronary syndrome: a review of antiplatelet therapy Changing roles of anticoagulant and antiplatelet treatment during percutaneous coronary intervention.Tirofiban in acute coronary syndromes.Percutaneous coronary revascularization in diabetics: from balloon angioplasty to drug-eluting stents.Acute coronary syndromes and diabetes mellitus.Biomarkers in acute coronary syndromes and their role in diabetic patients.Diabetes and percutaneous coronary intervention in the setting of an acute coronary syndrome.The acute reperfusion management of STEMI in patients with impaired glucose tolerance and type 2 diabetes.Non ST segment elevation acute coronary syndromes: A simplified risk-orientated algorithm.Present and evolving role of eptifibatide in the treatment of acute coronary syndromes.Platelet hyperactivity in type 2 diabetes: role of antiplatelet agents.Gender-related mortality trends among diabetic patients with ST-segment elevation myocardial infarction: insights from a nationwide registry 1997-2010 Highly electronegative LDL from patients with ST-elevation myocardial infarction triggers platelet activation and aggregation Antiplatelet therapy in diabetes: efficacy and limitations of current treatment strategies and future directions.Platelet perturbations in diabetes: implications for cardiovascular disease risk and treatment.Antithrombotic therapy in patients with diabetes mellitus and coronary artery disease.Emerging drugs for coronary artery disease. From past achievements and current needs to clinical promises.Current concepts on coronary revascularization in diabetic patients.Variability of clopidogrel response in patients with type 2 diabetes mellitus.Arterial thrombosis--insidious, unpredictable and deadly.2011 ACCF/AHA/SCAI guideline for percutaneous coronary intervention: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines and the Society for Cardiovascular Angiography and Interventi Antithrombotic therapy in patients with acute coronary syndrome and diabetes mellitus.Risk stratification and timing of revascularization: which patients benefit from early versus later revascularization?Diabetes mellitus and the heart.Platelet function profiles in patients with diabetes mellitus.Percutaneous coronary intervention in diabetic patients: should choice of stents be influenced?Update on platelet glycoprotein IIb/IIIa inhibitors: recommendations for clinical practice.Impact of Diabetes Mellitus on the Pharmacodynamic Effects of Ticagrelor Versus Clopidogrel in Troponin-Negative Acute Coronary Syndrome Patients Undergoing Ad Hoc Percutaneous Coronary Intervention.

P2860

Q24793107-0A7EDBC1-F019-4721-870F-9CA9BBE05687 Q26775125-29787DC4-89C2-472C-B783-75AB976DE1BC Q28167559-DEBBC95F-01C9-46AB-A1E5-0F7E9551AB13 Q28218066-6B5B14F6-D72A-4581-AAF7-9E760DF728E6 Q28219354-2A7C2B15-79E1-4690-A1CD-34524B91C0BD Q30490718-A1A8197D-10AC-4328-A595-AE94F5B4E677 Q33387192-8C70F18C-F587-4614-89F1-B330A6C5EC4F Q33393501-0FCCF09D-3D07-4475-9E2D-2A2B48D6CB41 Q33876187-2BCAA0D9-2F1E-424E-B189-53B7E688453D Q35141772-BDDDB604-54A2-490F-AF5B-9B1038997D71 Q35195203-9826A240-33F5-48D3-B1E0-71A7F89721EF Q35647167-0173429B-9F7C-4986-9573-76A2565B6340 Q35755253-9C115A00-EFD0-4E69-A7BA-16241C1D68F5 Q35808289-89A7BAE4-648A-48E3-9BD3-A6C74643270D Q36107187-89F27025-6F55-418E-A5B8-27927F51E436 Q36216817-689AE10C-640B-4234-831D-650766EE8925 Q36320553-10D3DB94-5DBD-4967-8966-18DB9DCFCB96 Q36333917-304EC72D-6DB8-4040-8541-F58F4551CBD7 Q36333923-4A2B480F-FE40-4117-B089-9FFBD12BB883 Q36333927-27B00DAD-DBF3-4D08-91B6-B779AA0DA136 Q36519924-ABA84920-2BFF-4280-B20A-8019287EC388 Q36815950-19F15836-BFDE-4246-9FC6-855494C9750B Q37184596-190DB16B-EC9A-4353-A86E-6882194BC893 Q37291908-5905E82B-6A04-43FA-8432-138199BA18A2 Q37334725-14FAD4B6-D628-46CD-94E8-D5751AB727EB Q37428365-A36A452E-1B29-41D6-BAE0-B8719488C2C2 Q37472064-31F2D570-6DF5-42EB-8B40-DE6891B54F80 Q37797795-9B23774D-5EC3-4140-B75D-16CA36179A82 Q37827882-80E21463-8283-4E79-A3DF-31266664C489 Q37926750-8BE1B3D9-53A2-4731-9830-F848BB2634BD Q37936014-51FBF007-3520-4060-B5F3-129BE691313D Q37953778-53D5F9E2-D40A-4E66-8F0F-3199D2F248FB Q37953885-B33FF0BA-7980-4088-B807-BA4FCCBECD81 Q37997963-B98A279D-C56F-4393-ABD5-7DA5826C46D2 Q38009702-8A7DE887-27BD-448A-8EAB-3F4E71B6D02B Q38018724-C8162C6F-2B9D-4A2C-A736-D57EC1EAFCDA Q38081078-F0E1852F-9312-449F-9F89-BF1D729ABA06 Q38101961-505CC9B9-5476-45F1-9FCE-34A424F8E895 Q38118745-17BDCFE0-30F4-45B2-BF15-0ECA479D344E Q38378830-DF026A3E-DAD3-4AA3-9FD1-57537C17EA6A

P2860

Platelet glycoprotein IIb/IIIa inhibitors reduce mortality in diabetic patients with non-ST-segment-elevation acute coronary syndromes.

http://www.wikidata.org/entity/Q43815690

description

2001 nî lūn-bûn

@nan

2001年の論文

@ja

2001年学术文章

@wuu

2001年学术文章

@zh

2001年学术文章

@zh-cn

2001年学术文章

@zh-hans

2001年学术文章

@zh-my

2001年学术文章

@zh-sg

2001年學術文章

@yue

2001年學術文章

@zh-hant

name

Platelet glycoprotein IIb/IIIa ...... tion acute coronary syndromes.

@en

Platelet glycoprotein IIb/IIIa ...... tion acute coronary syndromes.

@nl

type

label

Platelet glycoprotein IIb/IIIa ...... tion acute coronary syndromes.

@en

Platelet glycoprotein IIb/IIIa ...... tion acute coronary syndromes.

@nl

prefLabel

Platelet glycoprotein IIb/IIIa ...... tion acute coronary syndromes.

@en

Platelet glycoprotein IIb/IIIa ...... tion acute coronary syndromes.

@nl

P1433

Q43815690-FF732092-6053-461C-B881-B7CBE8E7AFB0

P1476

Q43815690-488A339A-EFCD-44FF-88E7-FE0FBD2BAD1D

P2093

Q43815690-14D47115-DCEE-49B6-ADA3-D428067A381A

Q43815690-1CC768EA-679F-4A94-8CBB-27D7C5033CF5

Q43815690-1DF8E876-B2C1-4250-934A-8C8D6D7AD40D

Q43815690-5CE094F2-3979-43A2-AA0E-47B6E461E61F

Q43815690-661DB96C-3533-4FDA-96EF-25980FDCC28F

Q43815690-88A1941E-0366-4D4D-8946-7BBFFC9A551B

Q43815690-9A39085C-ECF7-4EBF-AC4E-FCC9D211886A

Q43815690-AAF7BE1F-F593-4383-BA6F-D1E978910A82

Q43815690-AFBBC485-AE42-440C-9C68-9D9F1D5765F6

Q43815690-B02FAF5B-E3E8-484D-B6FE-6B6B0ADEEE9B

P304

Q43815690-ADDCDC66-8429-44A6-BDD7-373FE062DDE9

P31

Q43815690-3C3A4C5C-83F9-4CB4-A55F-D633AA1AE72C

Q43815690-b2deadc8-cfc7-4a18-847c-3bc1393206e6

P356

Q43815690-A13F135A-4970-4E26-A625-E7A718616CD2

P407

Q43815690-9603961F-17F0-4B03-ADE2-308FF3EF2FC2

P433

Q43815690-F77C386A-6775-41EC-82AE-8A8636BE040D

P478

Q43815690-9158348F-71D2-4F0A-A4A6-37BC811C2684

P50

Q43815690-145CEB95-05D3-4D14-A9A2-07F5FA2D4550

Q43815690-FBBDC6D3-2FCE-493A-9658-6C6C0EB75BDB

P577

Q43815690-8F037B8D-7A6F-4C66-B895-F6307FDC2C5D

P5875

Q43815690-C5396219-1BEA-477C-91AC-F22E693B4CF9

P698

Q43815690-46CF4C93-8787-4C74-B35A-424482F1B349

P356

P1433

P1476

Platelet glycoprotein IIb/IIIa ...... tion acute coronary syndromes.

@en

P2093

Bhatt DL

http://www.w3.org/2001/XMLSchema#string

Chew DP

http://www.w3.org/2001/XMLSchema#string

Hamm CW

http://www.w3.org/2001/XMLSchema#string

Heeschen C

http://www.w3.org/2001/XMLSchema#string

Kleiman NS

http://www.w3.org/2001/XMLSchema#string

Moliterno DJ

http://www.w3.org/2001/XMLSchema#string

Mukherjee D

http://www.w3.org/2001/XMLSchema#string

Roffi M

http://www.w3.org/2001/XMLSchema#string

Théroux P

http://www.w3.org/2001/XMLSchema#string

White HD

http://www.w3.org/2001/XMLSchema#string

P304

2767-2771

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1161/HC4801.100029

http://www.w3.org/2001/XMLSchema#string

P407

P433

23

http://www.w3.org/2001/XMLSchema#string

P478

104

http://www.w3.org/2001/XMLSchema#string

P50

P577

2001-12-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

11623613

http://www.w3.org/2001/XMLSchema#string

P698

11733392

http://www.w3.org/2001/XMLSchema#string